Bioblast Pharma (NASDAQ:ORPN) is scheduled to be issuing its quarterly earnings data on Thursday, February 22nd.
Shares of Bioblast Pharma (NASDAQ:ORPN) opened at $2.87 on Thursday. The firm has a market capitalization of $8.92, a price-to-earnings ratio of -1.12 and a beta of 0.37. Bioblast Pharma has a twelve month low of $1.49 and a twelve month high of $6.85.
Separately, ValuEngine upgraded Bioblast Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.
About Bioblast Pharma
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.